Endocarditis caused by Aerococcus urinae: a case report and review of literature Authors: Gobbo Giovanni, Papa Mario Virgilio, Girolami Bruno, Mazzitelli Maria, Biolo Marta, Sergi Giuseppe, Simioni Paolo Published: 2026 ABSTRACT BackgroundInfective endocarditis is an infectious disease associated with high morbidity and mortality; incidence has been increasing in recent decades. Most common causes of infective endocarditis are Staphylococcus aureus, Streptococci, and Enterococci. Bacteria of the genus Aerococcus are not frequent etiological agents of endocarditis; Aerococcus urinae is a gram-positive bacterium that usually causes common urinary tract infections but can sometimes cause invasive infections such as infective endocarditis. In the past, incidence of Aerococcus urinae infections has likely been underestimated because of its morphological features similar to Staphylococci and Streptococci.Case presentationWe describe the case of a 74-year-old Italian woman with mitral valve endocarditis who presented to the emergency department with focal neurological symptoms associated with cerebral septic embolization; despite the development of severe mitral insufficiency, the size of the vegetation, and the presence of septic embolization, the patient could not be treated with surgical valve replacement in the short term owing to the hemorrhagic evolution of the cerebral lesions, which contraindicated extracorporeal circulation. Antibiotic treatment with ampicillin and levofloxacin was administered for 8 weeks, and after that, the patient was transferred to a rehabilitation unit.Literature review and conclusionWe analyzed cases of infective endocarditis due to Aerococcus urinae described so far in the literature. A total of 68 cases were included in the analysis. Patients were more frequently male (71%); urological risk factors such as benign prostatic hypertrophy, recurrent urinary tract infections, and indwelling catheter were highly represented in the case series. Almost a third of the patients developed septic embolization, and the most common site of embolization was the brain. Mortality rate was about 26.5%. According to international guidelines, in addition to antibiotic therapy, surgical valve replacement should be considered in selected patients since it improves prognosis. Background Infective endocarditis (IE) is a potentially life-threatening severe infection of the endocardial surface, with high burden of morbidity and mortality. The infectious process may involve native heart valves, prosthetic valves, or intracardiac implanted devices. Incidence of IE has been increasing in recent decades, reaching a global prevalence of 1 million cases in 2019, of which 66,000 patients died [7]. IE is more frequent in elderly patients owing to predisposing valvular degenerative diseases; other recognized risk factors are intravenous drug use, prosthetic valves or intracardiac implanted devices, rheumatic or congenital heart diseases, immunosuppression, and diabetes mellitus [6]. The leading etiological cause of IE is Staphylococcus aureus (responsible for 31% of all cases), followed by viridans group Streptococci and Enterococci; IEs caused by the HACEK group pathogens (Haemophilus spp, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) are less common [29]. Clinical manifestations of IE are heterogeneous, potentially involving any organ. Possible complications of IE are structural destruction of the valve (abscess, perforation), severe valve incompetence, heart failure, and embolic and neurological complications. Diagnosis is based on Duke’s criteria, which include clinical, microbiological, and imaging findings; echocardiography is the first-line examination [15, 29]. In-hospital mortality of IE reaches 20%, increasing to 25–30% at 6 months, even though there are significant differences according to social and clinical settings and causative organism [6]. Aerococcus urinae (AU) is a gram-positive, catalase-negative bacterium. The genus Aerococcus was first defined in 1953, and four species have been identified in humans up to now: A. urinae, A. sanguicola, A. christensenii, and A. urinaehominis. AU probably belongs to the normal urinary tract flora and has been identified as a possible cause of urinary tract infections. However, it can also be associated with invasive infections such as urosepsis, IE, or, less frequently, spondylodiscitis, septic arthritis, odontogenic infections, or peritonitis in patients receiving peritoneal dialysis. Pathogenicity of AU is also associated with its capability to form biofilms on devices and stimulate platelet aggregation. In the past, the misidentification of AU as Staphylococci or Streptococci probably led to AU underdiagnosis owing to the similar morphology. Moreover, many cases of bacteremias caused by AU without an infectious source have been described: Not infrequently, AU has not been identified in the urine, even in the presence of typical urinary symptoms, because urine cultures have not been incubated in a CO2-rich atmosphere that enhances the growth of Aerococcus [30]. Aerococcus urinae is not known to be a common cause of IE; therefore, we investigated cases of IE caused by Aerococcus urinae described in literature so far. Case report A 74-year-old Italian woman presented to the emergency department with neurological symptoms characterized by the onset of slurred speech and lethargy 5 days prior. Her past medical history was remarkable for a single episode of atrial fibrillation at the age of 71 years treated with electrical cardioversion; moreover, she suffered from mild–moderate mitral insufficiency, cystocele with urinary incontinence, recurrent cystitis, and dental granulomas. On admission, the patient appeared hemodynamically stable although pyretic; physical examination showed a 4/6 mitral systolic murmur, faint right hemiparesis, and aphasia. Laboratory tests revealed an increase in inflammation parameters (white blood count, 20,370/µL; neutrophils, 17,810/µL; C-reactive protein, 149 mg/L) and nitrites and leukocytes in the urinalysis. An electrocardiogram (EKG) showed sinus rhythm without atrioventricular block. Transthoracic echocardiography (TTE) and blood and urine cultures were scheduled in the meantime, and empirical treatment with intravenous ceftriaxone 2 g/day was started. Computed tomography (CT) imaging of her brain showed a subacute ischemic left mesial temporo-occipital lesion (Fig. 1). Consequently, antiplatelet therapy with acetylsalicylic acid and thromboprophylaxis with enoxaparin were started. The 24-hour control CT scan revealed another ischemic area in the left mesial thalamic area, with further worsening of vision and rapid onset of a new right parieto-occipital intraparenchymal hemorrhagic lesion, with modest perilesional edema (Fig. 2). Antiplatelet therapy and antithrombotic prophylaxis were withdrawn and anti-edema therapy with mannitol was started; neurosurgeons excluded surgical treatment, and serial radiological monitoring was scheduled.Fig. 1Brain computed tomography on day 0: finding of subacute ischemic left temporo-parietal lesionFig. 2Brain computed tomography on day 6: appearance of right occipito-parietal intraparenchymal hematoma Brain computed tomography on day 0: finding of subacute ischemic left temporo-parietal lesion Brain computed tomography on day 6: appearance of right occipito-parietal intraparenchymal hematoma Blood cultures performed on admission came back positive for Corynebacterium imitans and Aerococcus urinae, while the urine culture was positive for Escherichia coli. Corynebacterium imitans was considered a contaminant since it grew only in a single blood culture bottle. TTE revealed severe mitral insufficiency with thickening of the posterior leaflet of the mitral valve, raising the suspicion of endocarditis. A subsequent transesophageal echocardiography (TEE) confirmed a 21 mm endocarditic vegetation destroying the posterior leaflet of the mitral valve, causing severe valve insufficiency (Fig. 3a,b).Fig. 3a Transesophageal echocardiography: endocarditic vegetation destroying the posterior leaflet of the mitral valve. b Transesophageal echocardiography: mitral valve endocarditis resulting in severe mitral insufficiency a Transesophageal echocardiography: endocarditic vegetation destroying the posterior leaflet of the mitral valve. b Transesophageal echocardiography: mitral valve endocarditis resulting in severe mitral insufficiency The associated cerebral hemorrhagic lesion contraindicated extracorporeal circulation, excluding urgent surgical valve replacement. A fundus oculi and a thoraco-abdominal CT documented several embolic lesions involving retina, spleen, and both kidneys (Fig. 4, 5).Fig. 4Abdominal computed tomography (day 20). A splenic infarction was detected, corresponding to the subcapsular hypodense lesion of the spleen (arrow)Fig. 5Abdominal computed tomography (day 20) showing embolization-related lesions, in particular, a kidney subcortical triangular hypodense area (arrow), corresponding to a kidney infarction Abdominal computed tomography (day 20). A splenic infarction was detected, corresponding to the subcapsular hypodense lesion of the spleen (arrow) Abdominal computed tomography (day 20) showing embolization-related lesions, in particular, a kidney subcortical triangular hypodense area (arrow), corresponding to a kidney infarction Three sets of follow-up blood cultures continued to be positive for Aerococcus urinae, and therapy was modified to intravenous ampicillin 2 g, six times a day, and intravenous levofloxacin 750 mg, once a day, according to antibiotic susceptibility (Table 1). Despite not fully supported by guidelines (supporting the use of a β-lactam, often with short-course aminoglycoside for synergy), this choice was driven by the synergistic effect of levofloxacin with ampicillin and by the persistent bacteremia, and to avoid toxicity seen with other agents such as vancomycin or aminoglycosides in elderly individuals, such as this patient.Table 1Aerococcus urinae antibiotic sensitivityBlood cultures day 7Aerococcus urinaeMICPenicillinS< = 0.008AmpicillinS0.015MeropenemS< = 0.015LevofloxacinS< = 0.250VancomycinS0.500MIC Minimum Inhibitory Concentration, S Susceptible Table 1Aerococcus urinae antibiotic sensitivityBlood cultures day 7Aerococcus urinaeMICPenicillinS< = 0.008AmpicillinS0.015MeropenemS< = 0.015LevofloxacinS< = 0.250VancomycinS0.500MIC Minimum Inhibitory Concentration, S Susceptible Aerococcus urinae antibiotic sensitivity MIC Minimum Inhibitory Concentration, S Susceptible Her clinical course was further complicated by catheter-related candidemia (Candida glabrata), treated with caspofungin, and recovery from a cardiocirculatory arrest secondary to respiratory failure, probably resulting from an aspiration episode. Cardiac surgeons definitively excluded mitral valve replacement owing to patient comorbidities and rapid clinical deterioration. The patient was treated with antibiotics for 8 weeks and transferred to the rehabilitation unit where she slowly recovered from most of her neurological disabilities. Subsequently, 3 months after the end of antibiotic therapy, the patient was re-admitted to the hospital for a new transient ischemic attack (TIA), presenting with dysarthria and right motor hemi-syndrome; she exhibited rapid neurological improvement of symptoms without evidence of acute lesions on brain magnetic resonance imaging (MRI). A new TEE documented a reduction in the size of mitral valve vegetation. Given the overall improvement in clinical status, the persisting embolic phenomena led to the consideration of mitral valve replacement once more. However, the patient declined the procedure and was subsequently discharged from the hospital. In the subsequent follow-up, the patient did not show symptoms or signs of recurrence of IE, with persistent negative blood cultures and normal inflammation parameters. She repeatedly confirmed refusal of surgical or percutaneous mitral valve correction. Systematic review update of existing literature Methods Information sources We performed a systematic literature review as an update of existing data. Embase, PubMed, and Cochrane databases were screened from any date to August 2024, with the search term strategy < “endocarditis” AND “Aerococcus urinae” > . Eligibility criteria Published articles identified with the search strategy were included if they were: (a) studies regarding cases of Aerococcus urinae endocarditis; (b) included population aged ≥ 18 years; (c) appeared in the full text of the original research paper; and (d) were observational or retrospective studies, case reports, or letters. Exclusion criteria were: (a) abstracts and editorials; (b) non-English language papers; and (c) animal model studies. Selection and data collection process This review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA; http://www.prisma-statement.org/) and Meta-Analysis of Observational Studies in Epidemiology guidelines [27]. References cited in the selected papers were examined to identify any other potentially eligible articles. After paper selection by a first reviewer (M.V.P), the entire process was repeated and confirmed by a second reviewer (G.G) to ensure validity of inclusion. Differences in opinion were discussed with a third reviewer (P.S) until consensus for inclusion or exclusion was reached. The Rayyan software, a web-based tool tailored for systematic review coordination, was utilized to expedite the screening phase [26]. Data extraction Titles and abstracts of selected articles were screened for relevance. The following data were extracted: [1] study design; [2] number of patients included; [3] age of participants; [4] sex; [5] presence of risk factors for IE; [6] valve involved by IE; [7] antibiotic class; [8] antibiotic therapy duration; [9] evidence of septic embolization; [10] site of embolization; [11] symptoms suggestive of cerebral embolization on admission; [12] patients treated with surgery; and [13] clinical outcomes (survival). Quality of studies Standardized tools have been developed to assess the methodological quality of articles included in systematic reviews. Two authors (G.G. and M.V.P) independently assessed study quality of included studies using a standardized tool adapted for our review. Studies were rated as having low, moderate, or high risk of bias [24] Results Overall, 190 studies were identified from the database searches, and 65 duplicates were excluded. After reviewing titles and abstracts, 49 records were eligible for inclusion; 39 papers were retrieved in full text and were examined in detail. (Fig. 6, PRISMA).Fig. 6 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram of the process of (and reasons for) including and excluding studies Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram of the process of (and reasons for) including and excluding studies The quality of studies included in our review was assessed as described in the Methods section. The results of the quality assessment of the studies are presented in Table 2.Table 2Quality assessment of case reportsStudyWas the exposure adequately ascertained?Was the outcome adequately ascertained?Were other alternative causes that may explain the observation ruled out?Were all important data cited?Was follow-up duration adequate?Risk of biasaReferenceAhmed, 2021YesNoYesYesNoModerate[1]Akinboboye, 2022YesYesYesNoYesLow[2]Al Asad, 2022NoYesYesNoYesModerate[32]Alozie, 2011YesYesYesNoYesLow[3]Bathina, 2019NoYesYesNoYesModerate[8]Bruegger, 2009YesYesYesNoNoModerate[5]De Jong, 2010YesNoYesYesNoModerate[16]Banerjee, 2022YesNoYesYesNoModerate[4]Ebnother, 2002YesYesYesYesYesLow[10]Feghaly, 2022NoYesYesYesYesLow[11]Gompelman, 2014YesNoYesYesNoModerate[12]Gritsch, 1999NoYesYesYesYesLow[13]Ho, 2010NoYesNoYesYesModerate[14]Khan, 2021YesYesNoNoYesModerate[18]Kass, 2008NoYesYesYesYesLow[17]Kotkar, 2016YesNoYesYesNoModerate[19]Kristensen, 1995NoYesNoNoYesHigh[20]Lattanzio, 2020NoNoYesYesYesModerate[25]Ludhwani, 2020YesYesYesYesYesLow[21]Martín-Guerra, 2020YesYesNoYesNoModerate[22]Melnick, 2016YesYesYesYesYesLow[23]Rosborough, 2020YesYesYesYesNoLow[31]Quadros Flores, 2024YesNoYesNoYesModerate[28]Samuelsson, 2018NoYesYesYesNoModerate[33]Schuur, 1999YesYesYesNoYesLow[34]Senneby, 2016YesYesYesYesYesLow[35]Siddiqui, 2016YesYesYesNoYesLow[37]Slany, 2007YesYesYesYesYesLow[39]Skov, 1995YesYesYesYesYesLow[38]Sunnerhagen, 2016YesYesYesYesYesLow[40]Tai, 2021YesYesYesYesYesLow[41]Tathireddy, 2017YesYesYesNoYesLow[42]Tekin, 2007YesNoYesYesNoModerate[43]Varughese, 2020YesNoYesYesNoModerate[45]Tiong, 2022YesYesYesYesYesLow[44]Westmoreland, 2014YesYesNoNoNoHigh[46]Yabes, 2018YesYesYesYesYesLow[47]Yee, 2023YesNoYesYesNoModerate[48]Zbinden, 1999YesNoYesNoNoHigh[49]Quality assessment of case reports was based on five questions; the risk of bias was graded as low (5 or 4 yes), moderate (3 yes), or high (2 or less yes) Table 2Quality assessment of case reportsStudyWas the exposure adequately ascertained?Was the outcome adequately ascertained?Were other alternative causes that may explain the observation ruled out?Were all important data cited?Was follow-up duration adequate?Risk of biasaReferenceAhmed, 2021YesNoYesYesNoModerate[1]Akinboboye, 2022YesYesYesNoYesLow[2]Al Asad, 2022NoYesYesNoYesModerate[32]Alozie, 2011YesYesYesNoYesLow[3]Bathina, 2019NoYesYesNoYesModerate[8]Bruegger, 2009YesYesYesNoNoModerate[5]De Jong, 2010YesNoYesYesNoModerate[16]Banerjee, 2022YesNoYesYesNoModerate[4]Ebnother, 2002YesYesYesYesYesLow[10]Feghaly, 2022NoYesYesYesYesLow[11]Gompelman, 2014YesNoYesYesNoModerate[12]Gritsch, 1999NoYesYesYesYesLow[13]Ho, 2010NoYesNoYesYesModerate[14]Khan, 2021YesYesNoNoYesModerate[18]Kass, 2008NoYesYesYesYesLow[17]Kotkar, 2016YesNoYesYesNoModerate[19]Kristensen, 1995NoYesNoNoYesHigh[20]Lattanzio, 2020NoNoYesYesYesModerate[25]Ludhwani, 2020YesYesYesYesYesLow[21]Martín-Guerra, 2020YesYesNoYesNoModerate[22]Melnick, 2016YesYesYesYesYesLow[23]Rosborough, 2020YesYesYesYesNoLow[31]Quadros Flores, 2024YesNoYesNoYesModerate[28]Samuelsson, 2018NoYesYesYesNoModerate[33]Schuur, 1999YesYesYesNoYesLow[34]Senneby, 2016YesYesYesYesYesLow[35]Siddiqui, 2016YesYesYesNoYesLow[37]Slany, 2007YesYesYesYesYesLow[39]Skov, 1995YesYesYesYesYesLow[38]Sunnerhagen, 2016YesYesYesYesYesLow[40]Tai, 2021YesYesYesYesYesLow[41]Tathireddy, 2017YesYesYesNoYesLow[42]Tekin, 2007YesNoYesYesNoModerate[43]Varughese, 2020YesNoYesYesNoModerate[45]Tiong, 2022YesYesYesYesYesLow[44]Westmoreland, 2014YesYesNoNoNoHigh[46]Yabes, 2018YesYesYesYesYesLow[47]Yee, 2023YesNoYesYesNoModerate[48]Zbinden, 1999YesNoYesNoNoHigh[49]Quality assessment of case reports was based on five questions; the risk of bias was graded as low (5 or 4 yes), moderate (3 yes), or high (2 or less yes) Quality assessment of case reports Quality assessment of case reports was based on five questions; the risk of bias was graded as low (5 or 4 yes), moderate (3 yes), or high (2 or less yes) In our review, we included 67 cases of endocarditis caused by Aerococcus urinae identified through the literature search and the one we observed in our clinic. Demographics and clinical characteristics are summarized in Table 3. Patients had a median age of 74 years (interquartile range [IQR], 60–80.5), and 53 (79%) were male. The vast majority of patients (71%, 48 individuals) presented urological risk factors, including indwelling catheter, suprapubic catheter, urethral stricture, benign prostatic hypertrophy (BPH), ureteral stent, history of urinary tract infection (UTI), nephrolithiasis, or phimosis. Moreover, 10% of patients (7 individuals) presented cardiovascular risk factors for infectious endocarditis such as bioprosthetic valve, aortic stenosis, and valve regurgitation; 9% of patients (6 individuals) had immunological alterations associated with malignancy and immunosuppressive therapy (Table 4). IE involved the aortic valve in most cases (39, 57.3%) and the mitral valve (28 cases, 41.2%). Five patients had IE involving multiple valves (7.4%); only one patient had IE involving a pacemaker (Table 5). Almost one-third of patients (20, 28%) presented embolization phenomena associated with IE. Embolization prevalence was similar in patients with IE of the aortic valve (12, 30% of patients with IE of the aortic valve) compared with those with IE of the mitral valve (11, 39% of patients with IE of the mitral valve). The most common site of embolization was brain (17), followed by kidney (5); other possible sites of embolization were lung (3), spleen (2), liver (1), and spine (1). Most patients (92%, 62 cases) were treated with beta-lactams, often associated with aminoglycosides (58%, 39 cases) or vancomycin (13%, 9 cases); other classes of antibiotics such as rifampicin or fluoroquinolones were rarely associated (Table 6). The mean duration of antibiotic therapy was 4 weeks (IQR 4–6). A total of 20 patients (29.9%) required surgical treatment of IE. The overall mortality rate was 26.5%.Table 3Included cases of infective endocarditis caused by Aerococcus urinae: main characteristicsnAuthorsYear*Age, yearsSexRisk factorValveAntibiotic classDurationEmbolizationSurgerySurvivalRef.1Skov199581MUTIAorticLACTAM/AG2 W/8 DNNN[38]2Kristensen199578MAortic stenosisAorticLACTAM/AG10 D–NN[20]3Gritsch199943MHepatitis CAorticLACTAM/AG5 DBrain, kidneyNN[13]4Schuur199989MTURPMitralLACTAM/AG7 DNNN[34]5Zbinden199948MASDMitralLACTAM/AG–Brain (NSA)NY[49]6Zbinden199979FUTIAorticLACTAM6 WBrainNY[49]7Ebnother200275MCystoscopyAorticLACTAM/AG6 WBrain, kidneyYY[10]8Tekin200768MBPHMitralLACTAM/AG; oral3 W; –NNY[43]9Kass200877MBPHAorticLACTAM/VAN–Brain, kidney, lungNN[17]10Bruegger200962MBPHMitral/aorticLACTAM/rifampicin; AG6 W; 2W–YY[5]11Ho201080MMalignancyAorticLACTAM6 W–YY[14]12De Jong201081MBPHMitralLACTAM/AG6 WNNY[16]13De Jong201078MIndwelling catheterAorticLACTAM–NNN[16]14De Jong201087MBPHMitral––NNN[16]15De Jong201078FUreteral stentAorticLACTAM/VAN2 WNNN[16]16Alozie201168MIndwelling catheterAorticLACTAM/AG6/2 WBrain (NSA)YY[3]17Kotkar201654MPhimosisMitralLACTAM6 WLung, spleenYY[19]18Senneby201687MMalignancyMitralLACTAM/AG–N–N[35]19Senneby201677MLiver failureAorticLACTAM/AG–N–Y[35]20Senneby201683MIndwelling catheterMitral (PV)LACTAM/AG–N–Y[35]21Senneby201673MSuprapubic catheterAorticLACTAM/AG–N–N[35]22Senneby201688FAortic stenosisAorticLACTAM/AG–N–Y[35]23Sunnerhagen201691MBPHMitralLACTAM/AG4 W/10 DN–Y[40]24Sunnerhagen201691MIndwelling catheterMitralLACTAM/AG4 W/10 DSpondyilitis–Y[40]25Sunnerhagen201689F–MitralLACTAM/AG4 W/10 DN–Y[40]26Sunnerhagen201686MUrethral strictureAorticLACTAM/AG4 W/10 DBrain–Y[40]27Sunnerhagen201683MUrethral strictureMitralLACTAM/AG4 W/10 DN–Y[40]28Sunnerhagen201680F–MitralLACTAM/AG4 W/10 DN–Y[40]29Sunnerhagen201677M–AorticLACTAM/AG4 W/10 DN–Y[40]30Sunnerhagen201675MBPHMitralLACTAM/AG4 W/10 DN–Y[40]31Sunnerhagen201674MSuprapubic catheter–LACTAM/AG4 W/10 DN–Y[40]32Sunnerhagen201665MIndwelling catheterMitralLACTAM/AG4 W/10 DN–Y[40]33Sunnerhagen201653MDysuriaAorticLACTAM/AG4 W/10 DN–Y[40]34Sunnerhagen201649FIntermittent catheterAorticLACTAM/AG4 W/10 DN–Y[40]35Sunnerhagen201681MIndwelling catheterMitralLACTAM/AG4 W/10 DN–Y[40]36Sunnerhagen201674FMalignancy–LACTAM/AG4 W/10 DN–Y[40]37Gompelman201642MNONEAorticLACTAM/AG6 WBrain (NSA), spleenYY[12]38Westmoreland201649M–AorticLACTAM/AG–N–Y[46]39Siddiqui201654MUrethral strictureTricuspid/aorticLACTAM/AG–NNN[37]40Melnick201674MBPHMitralLACTAM/AG4 WBrain (NSA)YN[23]41Tathireddy201769MCystoscopyAorticLACTAM/AG6 WNNY[42]42Tatyireddy201769MMalignancyAortic (PV)LACTAM12 WNYY[42]43Slany201769MMalignancyAorticLACTAMNYY[39]44Yabes201843MIndwelling catheterMitralLACTAM/AG–NYY[47]45Samuellson201884MPM, bladder cancerTricuspid, PMLACTAM6 WNNY[33]46Bathina201942MNephrolithiasisAortic/mitral/pulmonic––Brain (NSA), kidney, spleenNN[8]47Lattanzio202067MUTI/bioprosthetic valveAortic (PV)LACTAM6 WNYY[25]48Rosborough202092MValve regurgitationMitral/tricuspidLACTAM4 WBrain (NSA), liverNY[31]49Martin Guerra202061MIndwelling catheterAorticLACTAM/AG6 WNYY[22]50Varughese202043MUTI/bioprosthetic valveAortic (PV)LACTAM/VAN–NNY(31)51Ludhwani202059MUTIAorticVAN6 WNYY[21]52Tai202156FUTIAortic/mitralLACTAM/VAN2–4 WBrainYY[41]53Tai202154MUTIMitralAmpicillin6 WBrain, spleenYY[41]54Tai202179FUTIMitralLACTAM4 WLungNY[41]55Tai202172FUTIAorticAmpicillin4 WNNY[41]56Tai202146MUTIAortic/mitralLACTAM2 WBrainNN[41]57Tai202180MUTIMitralLACTAM/AG4 WNYY[41]58Tai202170MUTIMitralLACTAM/AG4 WNYY[41]59Ahmed202158MPhimosisAorticVAN6 WBrain (NSA)YY[1]60Khan202186FAortic stenosisAorticLACTAM/AG6 WNNN[18]61Feghaly202279M–AorticVAN6 WNNN[11]62Akinbboye202248MCocaine abuseAorticLACTAM/VAN; DAPTO2 WBrain (NSA)NN[2]63Wet Tiong202282MBPH/UTIAorticLACTAM6 WNYY[44]64Banerjee202261FImmunosoppressor, UTITRICUSPIDLACTAM6 WNNY[4]65Al-Asad202275MUTIAorticLACTAM1 WNNN[32]66Yee202380FHydroureteronephrosis/ nephrolithiasis/UTIAorticLACTAM/VAN4 WNNY[48]67Quadros Flores202484MPM, BPHMitralLACTAM/rifampicin10 WNYY[28]68Our case202474FValve regurgitationMitralLACTAM/VAN; quinolone8 WBrain (NSA), kidney, spleenNY*Year of publication. UTI urinary tract infection, ASD atrial septal defect, BPH: benign prostatic hypertrophy, PM pacemaker, PV prosthetic valve, NSA neurological symptoms on admission, LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin, W week, D day, Y yes, N no, TURP TransUrethral Resection of the Prostate, DAPTO DaptomycinTable 4Distribution of risk factors for IE caused by AURisk factor(n)Frequency (%)CV45.9IMM57.4URO4464.7URO and CV46.0URO and IMM11.5CV cardiovascular, IMM immunological, URO urologicalTable 5Valve involvement in IE caused by AUValve(n)Frequency (%)AO isolated3551.5AO and MI22.9AO, MI, and PUL11.5AO and TRI11.5MI isolated2435.3MI and TRI11.5TRI22.9PM11.5AO total3957.3MI total2841.2AO aortic, MI mitral, TRI tricuspid, PUL pulmonaryTable 6Antibiotic regimen used in IE caused by AUAntibiotic regimen(n)Frequency (%)LACTAM only1623.6LACTAM and AG3855.8LACTAM, AG, and rifampicin11.5LACTAM and rifampicin11.5LACTAM and VAN68.8LACTAM, VAN, and quinolone11.5VAN34.5LACTAM total6392.6LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin Table 3Included cases of infective endocarditis caused by Aerococcus urinae: main characteristicsnAuthorsYear*Age, yearsSexRisk factorValveAntibiotic classDurationEmbolizationSurgerySurvivalRef.1Skov199581MUTIAorticLACTAM/AG2 W/8 DNNN[38]2Kristensen199578MAortic stenosisAorticLACTAM/AG10 D–NN[20]3Gritsch199943MHepatitis CAorticLACTAM/AG5 DBrain, kidneyNN[13]4Schuur199989MTURPMitralLACTAM/AG7 DNNN[34]5Zbinden199948MASDMitralLACTAM/AG–Brain (NSA)NY[49]6Zbinden199979FUTIAorticLACTAM6 WBrainNY[49]7Ebnother200275MCystoscopyAorticLACTAM/AG6 WBrain, kidneyYY[10]8Tekin200768MBPHMitralLACTAM/AG; oral3 W; –NNY[43]9Kass200877MBPHAorticLACTAM/VAN–Brain, kidney, lungNN[17]10Bruegger200962MBPHMitral/aorticLACTAM/rifampicin; AG6 W; 2W–YY[5]11Ho201080MMalignancyAorticLACTAM6 W–YY[14]12De Jong201081MBPHMitralLACTAM/AG6 WNNY[16]13De Jong201078MIndwelling catheterAorticLACTAM–NNN[16]14De Jong201087MBPHMitral––NNN[16]15De Jong201078FUreteral stentAorticLACTAM/VAN2 WNNN[16]16Alozie201168MIndwelling catheterAorticLACTAM/AG6/2 WBrain (NSA)YY[3]17Kotkar201654MPhimosisMitralLACTAM6 WLung, spleenYY[19]18Senneby201687MMalignancyMitralLACTAM/AG–N–N[35]19Senneby201677MLiver failureAorticLACTAM/AG–N–Y[35]20Senneby201683MIndwelling catheterMitral (PV)LACTAM/AG–N–Y[35]21Senneby201673MSuprapubic catheterAorticLACTAM/AG–N–N[35]22Senneby201688FAortic stenosisAorticLACTAM/AG–N–Y[35]23Sunnerhagen201691MBPHMitralLACTAM/AG4 W/10 DN–Y[40]24Sunnerhagen201691MIndwelling catheterMitralLACTAM/AG4 W/10 DSpondyilitis–Y[40]25Sunnerhagen201689F–MitralLACTAM/AG4 W/10 DN–Y[40]26Sunnerhagen201686MUrethral strictureAorticLACTAM/AG4 W/10 DBrain–Y[40]27Sunnerhagen201683MUrethral strictureMitralLACTAM/AG4 W/10 DN–Y[40]28Sunnerhagen201680F–MitralLACTAM/AG4 W/10 DN–Y[40]29Sunnerhagen201677M–AorticLACTAM/AG4 W/10 DN–Y[40]30Sunnerhagen201675MBPHMitralLACTAM/AG4 W/10 DN–Y[40]31Sunnerhagen201674MSuprapubic catheter–LACTAM/AG4 W/10 DN–Y[40]32Sunnerhagen201665MIndwelling catheterMitralLACTAM/AG4 W/10 DN–Y[40]33Sunnerhagen201653MDysuriaAorticLACTAM/AG4 W/10 DN–Y[40]34Sunnerhagen201649FIntermittent catheterAorticLACTAM/AG4 W/10 DN–Y[40]35Sunnerhagen201681MIndwelling catheterMitralLACTAM/AG4 W/10 DN–Y[40]36Sunnerhagen201674FMalignancy–LACTAM/AG4 W/10 DN–Y[40]37Gompelman201642MNONEAorticLACTAM/AG6 WBrain (NSA), spleenYY[12]38Westmoreland201649M–AorticLACTAM/AG–N–Y[46]39Siddiqui201654MUrethral strictureTricuspid/aorticLACTAM/AG–NNN[37]40Melnick201674MBPHMitralLACTAM/AG4 WBrain (NSA)YN[23]41Tathireddy201769MCystoscopyAorticLACTAM/AG6 WNNY[42]42Tatyireddy201769MMalignancyAortic (PV)LACTAM12 WNYY[42]43Slany201769MMalignancyAorticLACTAMNYY[39]44Yabes201843MIndwelling catheterMitralLACTAM/AG–NYY[47]45Samuellson201884MPM, bladder cancerTricuspid, PMLACTAM6 WNNY[33]46Bathina201942MNephrolithiasisAortic/mitral/pulmonic––Brain (NSA), kidney, spleenNN[8]47Lattanzio202067MUTI/bioprosthetic valveAortic (PV)LACTAM6 WNYY[25]48Rosborough202092MValve regurgitationMitral/tricuspidLACTAM4 WBrain (NSA), liverNY[31]49Martin Guerra202061MIndwelling catheterAorticLACTAM/AG6 WNYY[22]50Varughese202043MUTI/bioprosthetic valveAortic (PV)LACTAM/VAN–NNY(31)51Ludhwani202059MUTIAorticVAN6 WNYY[21]52Tai202156FUTIAortic/mitralLACTAM/VAN2–4 WBrainYY[41]53Tai202154MUTIMitralAmpicillin6 WBrain, spleenYY[41]54Tai202179FUTIMitralLACTAM4 WLungNY[41]55Tai202172FUTIAorticAmpicillin4 WNNY[41]56Tai202146MUTIAortic/mitralLACTAM2 WBrainNN[41]57Tai202180MUTIMitralLACTAM/AG4 WNYY[41]58Tai202170MUTIMitralLACTAM/AG4 WNYY[41]59Ahmed202158MPhimosisAorticVAN6 WBrain (NSA)YY[1]60Khan202186FAortic stenosisAorticLACTAM/AG6 WNNN[18]61Feghaly202279M–AorticVAN6 WNNN[11]62Akinbboye202248MCocaine abuseAorticLACTAM/VAN; DAPTO2 WBrain (NSA)NN[2]63Wet Tiong202282MBPH/UTIAorticLACTAM6 WNYY[44]64Banerjee202261FImmunosoppressor, UTITRICUSPIDLACTAM6 WNNY[4]65Al-Asad202275MUTIAorticLACTAM1 WNNN[32]66Yee202380FHydroureteronephrosis/ nephrolithiasis/UTIAorticLACTAM/VAN4 WNNY[48]67Quadros Flores202484MPM, BPHMitralLACTAM/rifampicin10 WNYY[28]68Our case202474FValve regurgitationMitralLACTAM/VAN; quinolone8 WBrain (NSA), kidney, spleenNY*Year of publication. UTI urinary tract infection, ASD atrial septal defect, BPH: benign prostatic hypertrophy, PM pacemaker, PV prosthetic valve, NSA neurological symptoms on admission, LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin, W week, D day, Y yes, N no, TURP TransUrethral Resection of the Prostate, DAPTO Daptomycin Included cases of infective endocarditis caused by Aerococcus urinae: main characteristics *Year of publication. UTI urinary tract infection, ASD atrial septal defect, BPH: benign prostatic hypertrophy, PM pacemaker, PV prosthetic valve, NSA neurological symptoms on admission, LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin, W week, D day, Y yes, N no, TURP TransUrethral Resection of the Prostate, DAPTO Daptomycin Table 4Distribution of risk factors for IE caused by AURisk factor(n)Frequency (%)CV45.9IMM57.4URO4464.7URO and CV46.0URO and IMM11.5CV cardiovascular, IMM immunological, URO urological Distribution of risk factors for IE caused by AU CV cardiovascular, IMM immunological, URO urological Table 5Valve involvement in IE caused by AUValve(n)Frequency (%)AO isolated3551.5AO and MI22.9AO, MI, and PUL11.5AO and TRI11.5MI isolated2435.3MI and TRI11.5TRI22.9PM11.5AO total3957.3MI total2841.2AO aortic, MI mitral, TRI tricuspid, PUL pulmonary Valve involvement in IE caused by AU AO aortic, MI mitral, TRI tricuspid, PUL pulmonary Table 6Antibiotic regimen used in IE caused by AUAntibiotic regimen(n)Frequency (%)LACTAM only1623.6LACTAM and AG3855.8LACTAM, AG, and rifampicin11.5LACTAM and rifampicin11.5LACTAM and VAN68.8LACTAM, VAN, and quinolone11.5VAN34.5LACTAM total6392.6LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin Antibiotic regimen used in IE caused by AU LACTAM beta-lactam, AG aminoglycosides, VAN vancomycin Discussion and conclusion Incidence of IE has been increasing in recent decades [7]. On one hand, a possible explanation is the increasing aging of the population; on the other hand, diffusion of healthcare devices such as long-lasting venous catheters, indwelling devices (that is, pacemakers and implantable cardioverter-defibrillators), and cardiac prosthetic valves represent risk factors for the development of bacteremia. Aerococcus urinae is not a common cause of IE [15]. We examined cases of IE caused by Aerococcus urinae described in the literature, which identified 68 cases, including ours. This review currently includes additional cases of IE caused by AU; we analyzed the case reports individually, and this allowed us to evaluate additional information, such as the involvement of valve prostheses and the site of embolization, compared with previous reviews [32, 47]. According to our analysis, patients with IE caused by Aerococcus urinae were mainly elderly, with a median age of 74 years, similar to IE caused by other bacteria [15]. Male individuals comprised 79% of the included reports. This might depend on the greater prevalence in males of urological risk factors very common in IE caused by Aerococcus urinae, such as benign prostatic hypertrophy (BPH), indwelling bladder catheter, suprapubic catheterization, urological neoplasms, or UTI. The high frequency of urological risk factors supports the hypothesis that invasive infections caused by Aerococcus urinae, including IE, might originate from the urinary tract, even though several cases of invasive infection caused by Aerococcus urinae without growth of the bacterium in urine culture have been described (5). IE caused by Aerococcus urinae more frequently involved the aortic valve, followed by the mitral valve. A common risk factor for IE is the presence of prosthetic valves or cardiac indwelling devices; we found three cases of prosthetic valve infection caused by Aerococcus urinae in the literature, while only one case of pacemaker infection has been described. Clinical presentation of IE can be highly protean, depending on septic embolization phenomena. In our work, we analyzed the sites of septic embolization to emphasize the importance of considering IE in the differential diagnosis of several clinical settings. The most common embolization site was the brain (25% of patients), followed by kidneys and, less frequently, spleen, lungs, liver, and spine. Half of the patients with evidence of cerebral embolization had neurological symptoms at onset. IE should always be considered as a possible diagnosis in patients with neurological symptoms, mainly when multiple brain lesions are found. Treatment of IE is based on eradication of bacteria using antibiotics, sometimes combined with surgical treatment. Bactericidal antibiotics are preferred, and combination therapy is more effective than monotherapy [9]. Our analysis showed that the most common therapeutic regimen in IE caused by Aerococcus urinae was beta-lactams, often combined with aminoglycosides. Aminoglycosides have been widely used in the treatment of IE; these antibiotics are used in combination because of their synergistic action with bacterial wall inhibitor antibiotics. However, their use should be limited considering their significant side effects, including nephrotoxicity; when aminoglycosides are needed, their use should not exceed 2 weeks [9]. Our work highlights the importance of a multidisciplinary assessment of possible surgical treatment. Surgical treatment of IE has specific indications such as local valve complications, heart failure, and the presence of vegetations larger than 10 mm with embolization. About one-third of the patients in our review underwent cardiac surgery and appeared to have better survival (95%) compared with patients who were not treated surgically (survival 63%); however, several variables could influence these data, such as presence in the latter of severe comorbidities or compromised general status that contraindicated surgical treatment and contributed to a worse prognosis. IE has a high burden of morbidity and mortality, and up to 25–30% of patients die within 6 months of diagnosis [6]. According to our analysis, mortality from IE caused by Aerococcus urinae was 26.5%, similar to overall mortality from IE, but also similar to mortality reported from IE caused by streptococcal endocarditis. However, it was lower than mortality from IE caused by Staphylococci or Enterococci, which exceeds 40% [36]. Our patient did not receive surgical treatment, initially because of contraindications and finally owing to refusal; sequelae underline the burden of endocarditis in the clinical course of IE.